TSE:FRX Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis C$9.23 +0.15 (+1.65%) (As of 07/26/2024 ET) Add Compare Share Share Today's RangeC$9.20▼C$9.2350-Day RangeC$7.94▼C$9.8552-Week RangeC$7.80▼C$15.43Volume1,101 shsAverage Volume1,784 shsMarket CapitalizationC$252.16 millionP/E Ratio184.60Dividend Yield2.02%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades Get Fennec Pharmaceuticals alerts: Email Address Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Fennec Pharmaceuticals Stock (TSE:FRX)Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.Read More FRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FRX Stock News HeadlinesJuly 5, 2024 | insidertrades.comInsider Selling: Fennec Pharmaceuticals Inc. (TSE:FRX) Director Sells 2,431 Shares of StockMay 14, 2024 | finanznachrichten.deFennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateJuly 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.April 5, 2024 | finance.yahoo.comInsider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC)April 1, 2024 | seekingalpha.comFRX:CA Fennec Pharmaceuticals Inc.March 23, 2024 | seekingalpha.comFennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | finance.yahoo.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finanznachrichten.deFennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business UpdateJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.March 19, 2024 | ca.finance.yahoo.comStocks in play: Fennec Pharmaceuticals Inc.March 17, 2024 | markets.businessinsider.comFennec, Norgine Reach Licensing Deal To Commercialize Pedmarqsi In Europe, Australia, & New ZealandFebruary 29, 2024 | finance.yahoo.comFennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 ResultsFebruary 23, 2024 | finance.yahoo.comFENC Mar 2024 10.000 callFebruary 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Societal CDMO (SCTL)December 6, 2023 | finance.yahoo.comWith 31% stake, Fennec Pharmaceuticals Inc. (NASDAQ:FENC) seems to have captured hedge funds investors' interestDecember 1, 2023 | morningstar.comFennec Pharmaceuticals Inc FRXNovember 9, 2023 | seekingalpha.comFennec Pharmaceuticals Expands Possible TAM SignificantlyNovember 9, 2023 | finance.yahoo.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesSee More Headlines Receive FRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolTSE:FRX CUSIPN/A CIKN/A Webfennecpharma.com Phone+1-919-6364530FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C$0.05 Trailing P/E Ratio184.60 Forward P/E Ratio7.72 P/E GrowthN/ANet IncomeC$2.84 million Net Margins6.33% Pretax MarginN/A Return on Equity-1,005.59% Return on Assets8.57% Debt Debt-to-Equity Ratio1,040.68 Current Ratio6.93 Quick Ratio10.17 Sales & Book Value Annual SalesC$44.95 million Price / Sales5.61 Cash FlowC$0.79 per share Price / Cash Flow11.66 Book ValueC$0.11 per share Price / Book83.91Miscellaneous Outstanding Shares27,320,000Free FloatN/AMarket CapC$252.16 million OptionableNot Optionable Beta0.46 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Rostislav Raykov (Age 48)CEO & Director Comp: $1.2MMr. Robert C. Andrade (Age 49)Chief Financial Officer Comp: $817.74kMr. Adrian J. Haigh (Age 65)Chief Operating Officer Comp: $886.92kMr. Mark GowlandControllerMr. Lei FangPresident of Pharstat IncKey CompetitorsSolaris ResourcesTSE:SLSDalradian ResourcesTSE:DNAVBI VaccinesTSE:VBVChemtrade Electrochem Inc,TSE:CUSAndean Precious MetalsCVE:APMView All CompetitorsInsidersChris Anigeron RallisSold 1,173 sharesTotal: C$7,073.19 ($6.03/share)Rostislav Christov RaykovSold 2,431 sharesTotal: C$14,902.03 ($6.13/share)Adrian J. HaighSold 22,223 sharesTotal: C$207,029.47 ($9.32/share)Adrian J. HaighBought 22,222 shares on 4/15/2024Total: C$51,332.82 ($2.31/share)Chris Anigeron RallisSold 800 sharesTotal: C$8,360.00 ($10.45/share)View All Insider Transactions FRX Stock Analysis - Frequently Asked Questions How have FRX shares performed this year? Fennec Pharmaceuticals' stock was trading at C$15.16 on January 1st, 2024. Since then, FRX shares have decreased by 39.1% and is now trading at C$9.23. View the best growth stocks for 2024 here. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc. (TSE:FRX) issued its earnings results on Tuesday, May, 14th. The biopharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.67 by $0.11. The biopharmaceutical company had revenue of $34.21 million for the quarter, compared to the consensus estimate of $14.19 million. Fennec Pharmaceuticals had a negative trailing twelve-month return on equity of 1,005.59% and a net margin of 6.33%. How do I buy shares of Fennec Pharmaceuticals? Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Encanto Potash (EPO), Acadian Timber (ADN), Agellan Commercial Real Estate Invtmt TR (ACR.UN), AutoCanada (ACQ), ATCO (ACO.X) and Accord Financial (ACD). This page (TSE:FRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
